InvestorsHub Logo
Followers 7
Posts 496
Boards Moderated 0
Alias Born 11/15/2012

Re: inciteful post# 14345

Tuesday, 08/20/2013 8:20:57 AM

Tuesday, August 20, 2013 8:20:57 AM

Post# of 16750
Thanks. I wish I had more information to share.

I also wish that CLSN was moving more quickly, but we can't force the overall survival (OS) statistics out, as many people in the trial are still living!

That's why progression-free survival (PFS) is used more often to gauge the success of a trial. It doesn't take nearly as long to get results, and they are more focused on the underlying pathology.

I'm almost certain that Celsion will need another lengthy trial for Thermodox approval here in the U.S. market. And it's unclear whether they will get approval in China without one.

I am just so "upset" that the FDA screwed up the design of the P3 trial. WTH were they thinking!?! They have cost people's lives and investors hard-earned money by their misstep.